DEBATE Eventually, the debate boils down to whether removing patent rights will lead to lower R&D in diseases that are important for patients in developing economies. Ranjit Shahani Vice-Chairman & Managing Director, Novartis India Limited If people don't get a fair return in innovation, they won't invest in finding new cures for disease